Literature DB >> 28709828

Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.

Cody J Wenthur1, Xiaoqing Cai1, Beverly A Ellis1, Kim D Janda2.   

Abstract

Given the need for further improvements in anti-cocaine vaccination strategies, a chimeric hapten (GNET) was developed that combines chemically-stable structural features from steady-state haptens with the hydrolytic functionality present in transition-state mimetic haptens. Additionally, as a further investigation into the generation of an improved bifunctional antibody pool, sequential vaccination with steady-state and transition-state mimetic haptens was undertaken. While GNET induced the formation of catalytically-active antibodies, it did not improve overall behavioral efficacy. In contrast, the resulting pool of antibodies from GNE/GNT co-administration demonstrated intermediate efficacy as compared to antibodies developed from either hapten alone. Overall, improved antibody catalytic efficiency appears necessary to achieve the synergistic benefits of combining cocaine hydrolysis with peripheral sequestration.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Catalytic antibody; Chimeric hapten; Cocaine; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28709828      PMCID: PMC5584565          DOI: 10.1016/j.bmcl.2017.07.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  25 in total

1.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

Review 2.  Biologic Approaches to Treat Substance-Use Disorders.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

3.  Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

Authors:  Megan J Shram; Orit Cohen-Barak; Bijan Chakraborty; Merav Bassan; Kerri A Schoedel; Hussein Hallak; Eli Eyal; Sivan Weiss; Yossi Gilgun-Serki; Yossi Gilgun; Edward M Sellers; Janice Faulknor; Ofer Spiegelstein
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

4.  Hapten optimization for cocaine vaccine with improved cocaine recognition.

Authors:  Muthu Ramakrishnan; Berma M Kinsey; Rana A Singh; Thomas R Kosten; Frank M Orson
Journal:  Chem Biol Drug Des       Date:  2014-07-29       Impact factor: 2.817

5.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

6.  Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.

Authors:  Anat Maoz; Martin J Hicks; Shankar Vallabhjosula; Michael Synan; Paresh J Kothari; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Diana Martinez; George F Koob; Kim D Janda; Ronald G Crystal
Journal:  Neuropsychopharmacology       Date:  2013-05-10       Impact factor: 7.853

7.  Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine.

Authors:  Martin J Hicks; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Suzette M Evans; Richard W Foltin; David M Andrenyak; David E Moody; George F Koob; Kim D Janda; Rodolfo J Ricart Arbona; Michelle L Lepherd; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2014-03       Impact factor: 5.032

8.  Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Authors:  Orit Cohen-Barak; Jacqueline Wildeman; Jeroen van de Wetering; Judith Hettinga; Petra Schuilenga-Hut; Aviva Gross; Shane Clark; Merav Bassan; Yossi Gilgun-Sherki; Boaz Mendzelevski; Ofer Spiegelstein
Journal:  J Clin Pharmacol       Date:  2015-01-12       Impact factor: 3.126

9.  Flagellin as carrier and adjuvant in cocaine vaccine development.

Authors:  Jonathan W Lockner; Lisa M Eubanks; Jennifer L Choi; Jenny M Lively; Joel E Schlosburg; Karen C Collins; Daniel Globisch; Robin J Rosenfeld-Gunn; Ian A Wilson; Kim D Janda
Journal:  Mol Pharm       Date:  2015-01-07       Impact factor: 4.939

10.  The search for medications to treat stimulant dependence.

Authors:  Kyle M Kampman
Journal:  Addict Sci Clin Pract       Date:  2008-06
View more
  2 in total

1.  A plant-derived cocaine hydrolase prevents cocaine overdose lethality and attenuates cocaine-induced drug seeking behavior.

Authors:  Katherine E Larrimore; Latha Kannan; R Player Kendle; Tameem Jamal; Matthew Barcus; Kathryn Stefanko; Jacquelyn Kilbourne; Stephen Brimijoin; Chang-Guo Zhan; Janet Neisewander; Tsafrir S Mor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-05-06       Impact factor: 5.067

Review 2.  Catalytic Antibodies: Design, Expression, and Their Applications in Medicine.

Authors:  Daqun Zhao; Jie Chen; Xiaoyue Hu; Shujun Zhang
Journal:  Appl Biochem Biotechnol       Date:  2022-10-12       Impact factor: 3.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.